Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer
Molecular Omics · 2023
DOI: 10.1039/d3mo00042g ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, 2023. Verfasst von Daigo Gunji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Proteome Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan. jun_adachi@nibiohn.go.jp. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Colorectal cancer (CRC), a common malignant tumour of the gastrointestinal tract, is a life-threatening cancer worldwide. Mutations in KRAS and BRAF, the major driver mutation subtypes in CRC, activate the RAS pathway, contribute to tumorigenesis in CRC and are being investigated as potential therapeutic targets. Despite recent advances in clinical trials targeting KRASG12C or RAS downstream signalling molecules for KRAS-mutant CRC, there is a lack of effective therapeutic interventions. Therefore, understanding the unique molecular characteristics of KRAS-mutant CRC is essential for identifying molecular targets and developing novel therapeutic interventions. We obtained in-depth proteomics and phosphoproteomics quantitative data for over 7900 proteins and 38 700 phosphorylation sites in cells from 35 CRC cell lines and performed informatic analyses, including proteomics-based coexpression analysis and correlation analysis between phosphoproteomics data and cancer dependency scores of the corresponding phosphoproteins. Our results revealed novel dysregulated protein–protein associations enriched specifically in KRAS-mutant cells. Our phosphoproteomics analysis revealed activation of EPHA2 kinase and downstream tight junction signalling in KRAS-mutant cells. Furthermore, the results implicate the phosphorylation site Y378 in the tight junction protein PARD3 as a cancer vulnerability in KRAS-mutant cells. Together, our large-scale phosphoproteomics and proteomics data across 35 steady-state CRC cell lines represent a valuable resource for understanding the molecular characteristics of oncogenic mutations. Our approach to predicting cancer dependency from phosphoproteomics data identified the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Proteome Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan. jun_adachi@nibiohn.go.jp.
- Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan.
- Department of Surgery, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, 606-8507, Japan.
- Laboratory of Clinical and Analytical Chemistry, Center for Drug Design Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan.
- Laboratory of Proteomics and Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, 606-8501, Japan.
ORCID-Profile: Daigo Gunji, Ryohei Narumi, Satoshi Muraoka, Yoshiharu Sakai, Kazutaka Obama, Jun Adachi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Gunji, D., Narumi, R., Muraoka, S., Isoyama, J., Ikemoto, N., Ishida, M., Tomonaga, T., Sakai, Y., Obama, K., & Adachi, J. (2023). Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer. Molecular Omics. https://doi.org/10.1039/d3mo00042g
Vancouver
Gunji D, Narumi R, Muraoka S, Isoyama J, Ikemoto N, Ishida M, et al. Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer. Molecular Omics. 2023. doi:10.1039/d3mo00042g
BibTeX
@article{Gunji2023,
author = {Gunji, Daigo and Narumi, Ryohei and Muraoka, Satoshi and Isoyama, Junko and Ikemoto, Narumi and Ishida, Mimiko and Tomonaga, Takeshi and Sakai, Yoshiharu and Obama, Kazutaka and Adachi, Jun},
title = {Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer},
journal = {Molecular Omics},
year = {2023},
doi = {10.1039/d3mo00042g}
}
EUVIMED